公司資料
Northwest Biotherapeutics 股價、新聞與催化劑
- 股票代碼:
- NWBO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.16 USD (-3.26%)
收盤價
最後更新: 2026年9月18日
—
市值
股價為何變動
截至 2026年9月18日，NWBO 下跌 3.26%，收於 $0.1601。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Northwest Biotherapeutics is an immunotherapy company focused on cancer vaccines and personalized tumor treatment. Its business has been shaped by a long-duration and highly controversial development story.
所在地與產業分類
Headquartered in the United States and listed on OTC markets, Northwest sits in oncology biotechnology.
商業模式特徵
The company depends on clinical validation, regulatory progress, and the ability to convert vaccine science into value.
生技產業定位
Northwest is a highly speculative oncology name whose valuation is driven by high-uncertainty clinical outcomes.
未來催化劑
- Northwest Biotherapeutics’s catalyst is DCVax-L and any regulatory or commercial update that clarifies whether the long-running glioblastoma story still has a path. The stock remains heavily event-driven.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。